PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 219580-11-7
- Fòrmula: C28H41N7O3
- Peso molecular:523.67
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
FGFR1 |
FGFR2 |
PD173074 GMP (GMP) (100 nmol/L; 3-hour pre-incubation, followed by 10-day incubation with repeated 3-hour pre-incubations every 3 days) blocks FGF-induced endothelial differentiation of human adipose-derived stem cells, including reducing CD31 and eNOS mRNA expression, preventing capillary-like structure formation on Matrigel, and eliminating eNOS protein expression[1].
PD173074 GMP (GMP) (200 nM; 6 h) upregulates LEFTY1, LEFTY2, and FST and downregulates CRIPTO, NODAL, INHBA, INHBB, and NANOG in on-feeder human iPSCs, with no effect on NOMO1, NOMO2, NOMO3, NCLN, or OCT4[2].
PD173074 GMP (GMP) (200 nM; 6 h) downregulates LEFTY1, NODAL, and NANOG and upregulates FST in feeder-less human iPSCs, with no effect on CRIPTO, LEFTY2, or OCT4[2].
PD173074 GMP (GMP) (200 nM; 2-6 h) induces time-dependent downregulation of LEFTY1 (starting at 2 h), NODAL (at 6 h), LEFTY2 (at 6 h), and NANOG (starting at 4 h) in feeder-less human iPSCs, with no effect on CRIPTO or OCT4 over 6 h[2].
PD173074 GMP (GMP) (200 nM; 24 h) downregulates CRIPTO, LEFTY1, and NANOG in feeder-less human iPSCs[2].
PD173074 GMP (GMP) (200 nM; 6 h) reduces phosphorylation of SMAD2 and FGFR in feeder-less human iPSCs, with no effect on total SMAD2/3 or CRIPTO protein levels[2].
PD173074 GMP (GMP) (200 nM; 6 h) does not change the perinuclear localization of CRIPTO in feeder-less human iPSCs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:activin A-pretreated feeder-less human induced pluripotent stem cells (iPSCs)
-
Concentration:200 nM
-
Incubation Time:6 h (following 24 h pretreatment with 10 ng/mL activin A)
-
Result:Significantly increased the relative expression levels of LEFTY1 and LEFTY2.
Significantly decreased the relative expression level of NANOG.
Caused no significant change in the relative expression levels of CRIPTO, NODAL, and OCT4.
-
Cell Line:feeder-less human induced pluripotent stem cells (iPSCs)
-
Concentration:200 nM
-
Incubation Time:2 h; 4 h; 6 h
-
Result:Caused significant downregulation of LEFTY1 expression at 2 h, with further downregulation at 4 h and 6 h.
Significantly downregulated NODAL expression at 6 h.
Significantly downregulated NANOG expression starting at 4 h.
Caused no significant change in CRIPTO or OCT4 expression at any time point up to 6 h.
Downregulated LEFTY2 expression at 6 h.
-
Cell Line:feeder-less human induced pluripotent stem cells (iPSCs)
-
Concentration:200 nM
-
Incubation Time:6 h
-
Result:Significantly decreased the relative signal strength of phosphorylated SMAD2 (pSMAD2) and phosphorylated FGF receptor (pFGFR; ~60 kDa).
Caused no significant change in the relative signal strength of total SMAD2/3 or CRIPTO (25 kDa).
Did not alter the size or abundance of CRIPTO protein.
PD173074 GMP (50 mg/kg; p.o.; once daily; 14 d): In nude mouse models inoculated with H-69 human small cell lung cancer cells, it reduces intratumoral proliferation in the early stage of treatment, and this change can be detected by [18F] FLT-PET in vivo imaging between 7 and 14 days of treatment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice, bearing H-510 human small cell lung cancer xenografts[3]
-
Dosage:50 mg/kg
-
Administration:p.o.; once daily; 28 d
-
Result:Impaired tumor growth to a similar extent as single-agent cisplatin, increased the median survival of tumor-bearing mice compared with control animals, and did not affect tumor vasculature or lymph node metastasis.
Chemical Information
-
No. CAS 219580-11-7
-
Peso molecular 523.67
-
Fòrmula C28H41N7O3
-
SMILES
O=C(NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C3=CC(OC)=CC(OC)=C3)NC(C)(C)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz